Molecular Interplay between hypertension and dyslipidemia in cardiovascular pathogenesis: toward precision-based therapeutic strategies - Takeaways - MDSpire

Molecular Interplay between hypertension and dyslipidemia in cardiovascular pathogenesis: toward precision-based therapeutic strategies

  • By

  • Boming Cao

  • Jingyi Pei

  • Ling Kong

  • Ying Han

  • Guangli Yan

  • Xijun Wang

  • June 11, 2026

  • 0 min

Share

  • 1

    Hypertension and dyslipidemia significantly increase cardiovascular disease risk through interconnected molecular pathways.

  • 2

    Key pathways involved include the RAAS/PPAR axis, AMPK/SIRT1 signaling, and NLRP3 inflammasome activation.

  • 3

    The interplay between hypertension and dyslipidemia disrupts endothelial function and promotes chronic inflammation.

  • 4

    Emerging therapies like RAAS inhibitors combined with statins and newer agents aim to improve clinical outcomes.

  • 5

    A precision medicine framework is needed to address the synergistic pathophysiology of hypertension and dyslipidemia.

Original Source(s)

Molecular Interplay between hypertension and dyslipidemia in cardiovascular pathogenesis: toward precision-based therapeutic strategies

  • by Boming Cao, Jingyi Pei, Ling Kong, Ying Han, Guangli Yan, Xijun Wang

  • June 11, 2026

Related Content

Optimizing Food-Is-Medicine Programs for High Blood Pressure—Reply

How Quickly Are Patients Reaching Quadruple HFrEF Therapy?

Delays in initiating guideline-directed quadruple therapy may increase early clinical risk in heart failure with reduced ejection fraction.

Case Report: A case of acute anterior wall myocardial infarction caused by stent fracture in the left anterior descending artery